Mode
Text Size
Log in / Sign up
N/A N=24 Randomized Treatment

A Pilot Feasibility Trial of a Tailored Intervention to Improve Adherence in Adolescents and Young Adults With Cancer

Cancer · Adherence, Medication

Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Enrollment Rate — 70 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Tailored Program (Behavioral); Feedback Program (Behavioral)
Age
Pediatric, Adult · 15+ yrs
Sex
All
Sponsor
Children's Hospital Medical Center, Cincinnati
Primary completion
Nov 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Enrollment Rate
70
SECONDARY
Retention Rate
56
SECONDARY
Intervention Fidelity: Contact
10
SECONDARY
Intervention Fidelity: Length
8
SECONDARY
Intervention Fidelity: Duration
10
SECONDARY
Intervention Fidelity: Content
12
SECONDARY
Assessment Completion
12; 12
SECONDARY
System Usability Scale
80.42; 81.25
SECONDARY
"Adjective Rating Scale" (Measure of Usability)
5.92; 5.75
SECONDARY
Number of Participants Rating Behavioral Treatment Acceptability as 4 or Greater
11; 8
SECONDARY
Medical Adherence Measure
97.62; 90.28
SECONDARY
Electronically Monitored Medication Adherence
85.44; 63.25

Summary

A pilot feasibility randomized clinical trial comparing a tailored intervention to uniform standard of care will be conducted. A total of 40 AYAs with cancer will be randomized to one of the two programs. Data will be collected to explore the hypotheses that the intervention meets pre-established enrollment, retention, fidelity, and data completion feasibility criteria and that AYAs will rate the intervention as easy to use and acceptable.

Eligibility Criteria

Inclusion Criteria

  • Patient between 15 and 24 years of age
  • Patient diagnosis of cancer
  • Patient prescribed oral chemotherapy or prophylactic medication

Exclusion Criteria

  • Patient is not fluent in English
  • Patient evidences significant cognitive deficits per medical team
  • Patient's medical status or treatment precludes participation per medical team, patient, or caregiver
  • Patient demonstrates greater than or equal to 95% adherence during run-in period
  • Patient declines to use electronic monitoring device
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05706610). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search